表紙:肺動脈高血圧症:疫学的予測
市場調査レポート
商品コード
534965

肺動脈高血圧症:疫学的予測

Pulmonary Arterial Hypertension - Epidemiology Forecast to 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 98 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.86円
肺動脈高血圧症:疫学的予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 98 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の肺動脈高血圧症 (PAH) の疫学的予測について分析し、疾患の概要や現在の治療手法/アルゴリズム、世界全体および主要国 (米国・欧州諸国・日本) での有病者数・リスク患者数の動向見通し、今後の医薬品開発・治験の見通しなどについて調査しております。

第1章 分析概略

第2章 肺動脈高血圧症 (PAH):概要

  • 徴候と症状
  • 肺動脈高血圧症 (PAH) の分類
  • PAHの機能的分類
  • 病因
  • リスク要因
  • 病態生理
  • 診断方法
  • 治療方法

第3章 疫学と患者人口

  • 主な調査結果
  • 患者人口と予測パラメーター
  • 主要7ヶ国 (7MM) の肺動脈高血圧症 (PAH) の有病者数
    • 米国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • 日本

第4章 肺動脈高血圧症 (PAH) の疫学:国別

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第5章 付録

第6章 DelveInsightのサービス内容

第7章 免責事項

第8章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Pulmonary Arterial Hypertension (PAH) Epidemiology, and Key Events (2017-2030)
  • Table 2: Pulmonary Arterial Hypertension (PAH)
  • Table 3: Hemodynamic profiles of pulmonary hypertension
  • Table 4: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
  • Table 5: Total Prevalent Population of PAH in the United States (2017-2030)
  • Table 6: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
  • Table 7: Gender specific Prevalence of PAH in the United States (2017-2030)
  • Table 8: Total Prevalent Population of PAH in Germany (2017-2030)
  • Table 9: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
  • Table 10: Gender specific Prevalence of PAH in Germany (2017-2030)
  • Table 11: Total Prevalent Population of PAH in France (2017-2030)
  • Table 12: Sub-type Specific Prevalence of PAH in France (2017-2030)
  • Table 13: Gender specific Prevalence of PAH in France (2017-2030)
  • Table 14: Total Prevalent Population of PAH in Italy (2017-2030)
  • Table 15: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Table 16: Gender specific Prevalence of PAH in Italy (2017-2030)
  • Table 17: Total Prevalent Population of PAH in Spain (2017-2030)
  • Table 18: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Table 19: Gender specific Prevalence of PAH in Spain (2017-2030)
  • Table 20: Total Prevalent Population of PAH in the UK (2017-2030)
  • Table 21: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
  • Table 22: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
  • Table 23: Total Prevalent Population of PAH in Japan (2017-2030)
  • Table 24: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
  • Table 25: Gender specific Prevalence of PAH in Japan (2017-2030)
  • Table 26: Recommendations for efficacy of drug monotherapy for PAH (group 1) according to WHO functional class.
  • Table 27: Recommendations for efficacy of initial drug combination therapy for PAH (group 1) according to WHO functional class
  • Table 28: Recommendations for efficacy of sequential drug combination therapy for PAH (group 1) according to WHO functional class
  • Table 29: Organizations contributing toward Pulmonary Arterial Hypertension

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)
  • Figure 3: Classification of Pulmonary Arterial Hypertension (PAH)
  • Figure 4: Functional Classification of PAH
  • Figure 5: Risk Factors of Pulmonary Arterial Hypertension
  • Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 7: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 8: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 9: ESC/ERS Guidelines for the diagnosis of pulmonary hypertension
  • Figure 10: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
  • Figure 11: Prevalence of PAH in the United States (2017-2030)
  • Figure 12: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
  • Figure 13: Gender specific Prevalence of PAH in the United States (2017-2030)
  • Figure 14: Total Prevalent Population of PAH in Germany (2017-2030)
  • Figure 15: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
  • Figure 16: Gender specific Prevalence of PAH in Germany (2017-2030)
  • Figure 17: Total Prevalent Population of PAH in France (2017-2030)
  • Figure 18: Sub-type Specific Prevalence of PAH in France (2017-2030)
  • Figure 19: Gender specific Prevalence of PAH in France (2017-2030)
  • Figure 20: Total Prevalent Population of PAH in Italy (2017-2030)
  • Figure 21: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Figure 22: Gender specific Prevalence of PAH in Italy (2017-2030)
  • Figure 23: Total Prevalent Population of PAH in Spain (2017-2030)
  • Figure 24: Sub-type Specific Prevalence of PAH in Spain (2017-2030)
  • Figure 25: Gender specific Prevalence of PAH in Spain (2017-2030)
  • Figure 26: Total Prevalent Population of PAH in the UK (2017-2030)
  • Figure 27: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
  • Figure 28: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
  • Figure 29: Total Prevalent Population of PAH in Japan (2017-2030)
  • Figure 30: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
  • Figure 31: Gender specific Prevalence of PAH in Japan (2017-2030)
  • Figure 32: Treatment Options for Pulmonary Arterial Hypertension (PAH)
  • Figure 33: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 34: Unmet Needs of PAH
目次
Product Code: DIEI0792

DelveInsight's 'Pulmonary Arterial Hypertension - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Pulmonary Arterial Hypertension Disease Understanding

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Pulmonary Arterial Hypertension in 7MM was found to be 70,774, in the year 2017.

Report Scope:

  • The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool in 7MM

Key strengths

  • 11 Year Forecast of Pulmonary Arterial Hypertension epidemiology
  • 7MM Coverage
  • Total Incident Cases of PAHs
  • Incident Cases according to segmentation: (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool)

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Epidemiology Overview at a Glance

  • 4.1. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017
  • 4.2. Patient Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Classification of Pulmonary Arterial Hypertension (PAH)
    • 5.3.1. WHO classification
    • 5.3.2. Functional Classification of PAH
  • 5.4. Etiology
  • 5.5. Risk factors
  • 5.6. Pathophysiology
  • 5.7. Diagnosis
    • 5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Population and Forecast Parameters
  • 6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

  • 7.1. The United States
    • 7.1.1. Total Prevalent Patient Population of PAH in the United States
    • 7.1.2. Sub-type Specific Prevalence of PAH in the United States
    • 7.1.3. Gender specific Prevalence of PAH in the United States
  • 7.2. Germany
    • 7.2.1. Total Prevalent Patient Population of PAH in Germany
    • 7.2.2. Sub-type Specific Prevalence of PAH in Germany
    • 7.2.3. Gender specific Prevalence of PAH in Germany
  • 7.3. France
    • 7.3.1. Total Prevalent Patient Population of PAH in France
    • 7.3.2. Sub-type Specific Prevalence of PAH in France
    • 7.3.3. Gender specific Prevalence of PAH in France
  • 7.4. Italy
    • 7.4.1. Total Prevalent Patient Population of PAH in Italy
    • 7.4.2. Sub-type Specific Prevalence of PAH in Italy
    • 7.4.3. Gender specific Prevalence of PAH in Italy
  • 7.5. Spain
    • 7.5.1. Total Prevalent Patient Population of PAH in Spain
    • 7.5.2. Sub-type Specific Prevalence of PAH in Spain
    • 7.5.3. Gender specific Prevalence of PAH in Spain
  • 7.6. The United Kingdom
    • 7.6.1. Total Prevalent Patient Population of PAH in the UK
    • 7.6.2. Sub-type Specific Prevalence of PAH in the UK
    • 7.6.3. Gender specific Prevalence of PAH in the United Kingdom
  • 7.7. Japan
    • 7.7.1. Total Prevalent Patient Population of PAH in Japan
    • 7.7.2. Sub-type Specific Prevalence of PAH in Japan
    • 7.7.3. Gender specific Prevalence of PAH in Japan

8. Treatment Algorithm

  • 8.1. Current Treatment Practices
  • 8.2. Treatment Guidelines
    • 8.2.1. CHEST Guidelines [The United States]
    • 8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies

  • 10.1. A Rare Case of Drug Induced PAH
  • 10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Appendix

  • 12.1. Bibliography
  • 12.2. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight